CFHR5

Across TCGA pan-cancer cohorts, CFHR5 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CFHR5 data layer compared with 16 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CFHR5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFHR5 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

DLBC, STAD, and SCLC are the cancer types where CFHR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
STAD	DFS	Median	III,IV	1.000	0.337	.038	22	view →
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
LUAD	OS	Median	III,IV	0.147	0.679	.001	12	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	9	view →
COAD	OS	Median	All	0.650	0.871	.007	9	view →
LIHC	DFS	Median	All	0.096	0.543	.028	6	view →
PRAD	DFS	Median	All	0.617	0.886	.041	6	view →
UCEC	DFS	Median	All	0.933	0.626	.033	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
MESO	OS	Median	All	0.169	0.556	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CFHR5–DLBC (OS)

Open the DLBC breakdown →